Crossmark

Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer

Crossref DOI link: https://doi.org/10.1038/bjc.2015.103

Published Online: 2015-04-16

Published Print: 2015-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ohkawa, S

Okusaka, T

Isayama, H

Fukutomi, A

Yamaguchi, K

Ikeda, M

Funakoshi, A

Nagase, M

Hamamoto, Y

Nakamori, S

Tsuchiya, Y

Baba, H

Ishii, H

Omuro, Y

Sho, M

Matsumoto, S

Yamada, N

Yanagimoto, H

Unno, M

Ichikawa, Y

Takahashi, S

Watanabe, G

Wakabayashi, G

Egawa, N

Tsuda, M

Hosotani, R

Hamada, C

Hyodo, I
License Information

Text and Data Mining valid from 2015-04-01
More Information

Article History

Received: 9 December 2014

Revised: 7 February 2015

Accepted: 23 February 2015

First Online: 16 April 2015

Competing interests

: Hiroyuki Isayama received honoraria from Yakult Honsha Co., Ltd. and Taiho Pharmaceutical; Chikuma Hamada has received consulting fees from Yakult Honsha Co., Ltd.. The remaining authors declare no conflict of interest.